Corbus Pharma Files 10-Q for Q1 2025

Ticker: CRBP · Form: 10-Q · Filed: May 6, 2025 · CIK: 1595097

Sentiment: neutral

Topics: 10-Q, financials, pharmaceuticals

TL;DR

CRBP 10-Q filed for Q1 2025. Financials and agreements updated.

AI Summary

Corbus Pharmaceuticals Holdings, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information, including assets and liabilities, and references various agreements and plans such as the CFF Warrant, Loan Agreement with KTwo Health Ventures LLC, and the 2014 Equity Incentive Plan. The company's business address is 500 River Ridge Drive, Norwood, MA.

Why It Matters

This filing provides investors with an update on Corbus Pharmaceuticals' financial health and operational status for the first quarter of 2025, crucial for investment decisions.

Risk Assessment

Risk Level: medium — The filing is a routine 10-Q, but the company operates in the volatile pharmaceutical sector, which inherently carries significant risks.

Key Players & Entities

FAQ

What is the reporting period for this 10-Q filing?

The Conformed Period of Report is 20250331, indicating the first quarter of 2025.

What is Corbus Pharmaceuticals' primary business classification?

The Standard Industrial Classification is 'PHARMACEUTICAL PREPARATIONS [2834]'.

What is the company's business address?

The business address is 500 River Ridge Drive, Norwood, MA, 02062.

Are there any specific loan agreements mentioned in the filing details?

Yes, a 'LoanAgreementMember' is mentioned in relation to 'KTwoHealthVenturesLLCMember' with a date of 2023-06-01.

What type of financial instruments are mentioned regarding fair value measurements?

The filing mentions 'MoneyMarketFundsMember', 'USTreasurySecuritiesMember', and 'CommercialPaperMember' in the context of 'FairValueMeasurementsRecurringMember'.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 6, 2025 regarding Corbus Pharmaceuticals Holdings, Inc. (CRBP).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing